MENRIUM 5-2
LOE ApproachingNDAORALTABLET
Approved
Jul 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MENRIUM 5-2 is an oral tablet small-molecule NDA approved by Roche in 1966. The generic name and mechanism of action are unknown, limiting assessment of therapeutic positioning. Patient population and clinical indication cannot be determined from available data.
LOE Approaching
This product is approaching loss of exclusivity with minimal current commercial momentum; career roles likely focus on legacy brand management or transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No active job postings are linked to MENRIUM 5-2, reflecting its LOE-approaching lifecycle and minimal commercial momentum. Career roles on this product are typically focused on legacy brand management, compliance, and transition rather than growth and innovation.
Brand ManagerMedical Science Liaison
Worked on MENRIUM 5-2 at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.